NCT04160377 is a Phase 2 clinical trial of Fluvoxamine in Depressive Disorder, sponsored by Lingjiang Li.

Who is sponsoring NCT04160377?

NCT04160377 is sponsored by Lingjiang Li.

What drugs are being tested in NCT04160377?

Interventions in NCT04160377: Fluvoxamine.

What condition does NCT04160377 study?

NCT04160377 studies Depressive Disorder, Endogenous Depression, Melancholia.

Is NCT04160377 still recruiting?

NCT04160377 is currently status unknown. Last updated 12 April 2022.

Last reviewed 2022-04-12 · How we verify

NCT04160377

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Trial of Fluvoxamine for Melancholia

Status unknown Phase 2 Last updated 12 April 2022

What this trial tests

Phase 2 trial testing Fluvoxamine in Depressive Disorder in 150 participants. Status unknown.

Timeline

1 August 2019

Primary endpoint
30 June 2022

30 September 2022

Quick facts

Lead sponsor	Lingjiang Li
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	150
Start date	1 August 2019
Primary completion	30 June 2022
Estimated completion	30 September 2022
Sites	1 location across China

Drugs / interventions tested

Fluvoxamine (FLUVOXAMINE) — full drug profile →

Conditions studied

Depressive Disorder — all drugs for Depressive Disorder →
Endogenous Depression — all drugs for Endogenous Depression →
Melancholia — all drugs for Melancholia →

Sponsor

Lingjiang Li

Who can join

Adults 18 to 55, any sex, with Depressive Disorder or Endogenous Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims at investigating the special effectiveness of antidepressant effect of Fluvoxamine for endogenous depression. The investigators also aim to assess the effect of Fluvoxamine on the multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in depression patients with melancholic features. The investigators further aim to identify the predictors of Fluvoxamine's antidepressant effeect using the above techniques.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Prediction of Clinical Outcomes With EEG Microstate in Patients With Major Depressive Disorder.
Yan D, Liu J, Liao M, Liu B, et al · · 2021 · cited 35× · PMID 34483990 · DOI 10.3389/fpsyt.2021.695272
Effect of fluvoxamine on plasma interleukin-6 in patients with major depressive disorder: a prospective follow-up study.
Li X, Yan D, Liao M, Zhang L, et al · · 2023 · cited 4× · PMID 37304432 · DOI 10.3389/fpsyt.2023.1163754
Advancing depression treatment: the role of sigma receptor ligands.
Zhang P, Ning Z, Chen H, Chen J, et al · · 2025 · PMID 41378345 · DOI 10.3389/fnins.2025.1691987

Verify or expand the search:

Other trials of Fluvoxamine

Trials testing the same drug.

NCT06969287 — Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery · Phase 3 · recruiting
NCT07359482 — sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 · Phase 3 · not yet recruiting
NCT06821698 — To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers · Phase 1 · completed
NCT06232109 — Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects · Phase 1 · completed
NCT05888207 — A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects · Phase 1 · completed

Other recruiting trials for Depressive Disorder

Currently open trials in the same condition.

NCT07290153 — Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC · recruiting
NCT07100951 — Comparing Brief Psychoanalytic Couple Therapy and Emotionally Focused Therapy in Reducing Relationship Distress · NA · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06901739 — Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity. · NA · recruiting
NCT06724666 — Transdiagnostic Internet-delivered Intervention for Adolescents With Anxiety and Depression · NA · recruiting

Other Lingjiang Li trials

Trials by the same sponsor.

NCT03932825 — Nitrous Oxide for Major Depressive Disorder · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04160377 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lingjiang Li
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04160377.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing